New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
11:32 EDTSKBISkystar Bio-Pharma provides update on patent portfolio
Skystar Bio-Pharmaceutical announced the following updates to its patent portfolio: China's State Intellectual Property Office granted the company patents in application status for two new products. Additional two patents have application pending and review status with SIPO. Patent for one product in development expired, but the company retains know-how and exclusive rights to sell and market the product through 2020. Skystar previously submitted patent applications for Live Trivalent Attenuated Coccidiosis for poultry, and Multi-Immune Transfer Factor, an immunity boosting supplement, have been accepted by China's State Intellectual Property Office. SIPO has issued to Skystar patent numbers 2013103474397 and 2013102595286, respectively, in connection with these applications. Skystar is currently waiting for the SIPO office to issue the Company physical patent certificates for the two products. In addition, Skystar has applied to China's SIPO and was issued two additional patent application numbers 2014100550285 and 2014100559364, pending completion of the SIPO patent application review.
News For SKBI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
16:18 EDTSKBISkystar Bio-Pharma announces receipt of Nasdaq non-compliance letter
Skystar Bio-Pharmaceutical Company announced that on August 19, the Company received a notification from the Nasdaq Stock Market informing the Company that because it had not filed its Quarterly Report on Form 10-Q for the quarter ended June 30, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Company previously submitted a plan of compliance to Nasdaq, responded to an initial request for additional information from Nasdaq, and is preparing responses to a second request for additional information from Nasdaq. If its plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days from the date of its initial delinquent filing, or until October 12, to regain compliance.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use